US · Healthcare · Biotechnology
EPS came in at -0.58 against a street estimate of -0.58 — a beat of 0.0%.
Analysts rate Veradermics, Incorporated a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $163.50.
| Fund | Stake |
|---|---|
| Vanguard Fiduciary Trust Co | 0.34% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 VERADERMICS, INCORPORATED – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash and equivalents: $319.3 million as of June 30, 2026, up from $21.8 mil | 2026-08-11 |
| Results announced · Q3 2026 VERADERMICS, INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $819.9 million as of June 30, 20 | 2026-08-11 |
| Reg FD disclosure · Q3 2026 VERADERMICS, INC - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Veradermics, Incorporated (ticker: MANE, NYSE) • Report date: July 15, 2026 • Status | 2026-07-15 |
| Quarterly report · Q1 2026 VERADERMICS, INCORPORATED – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Company completed Initial Public Offering (IPO) on February 5, 2026: issued | 2026-05-12 |
| Results announced · Q2 2026 VERADERMICS, INC. – Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Cash Position: $390.8 million in cash, cash equivalents, and marketable securities a | 2026-05-12 |
| Material agreement · Q2 2026 VERADERMICS, INCORPORATED – FORM 8-K SUMMARY HEADLINE NUMBERS • Public offering closed May 1, 2026: 3,843,790 shares at $100.00 per share • Public o | 2026-05-01 |
| Annual report FY2025 VERADERMICS, INC. - FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Veradermics, Inc. (Ticker: MANE, NYSE) • Fiscal Year Ended: D | 2026-03-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Veradermics, Incorporated — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.